Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222831
Title: | Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study |
Author: | Bento, Leyre Gutiérrez García, Antonio Manuel Martínez, Carmen Ortí Verdet, María Consejo Sorribes, Marina Carolina Caballero, Ana Peña, Marta Pérez, Ariadna Jiménez Ubieto, Ana Medina, Lucía Bastos Oreiro, Mariana Fernández Caldas-González, Paula Navarro, Belén Salcedo, Isabel Abrisqueta, Pau Español, Ignacio Cornago Navascues, Javier Martín Moro, Fernando García, Lucía Gómez, Pilar Varela, María Rosario Puente, María Zanabili, Joud Zudaire, Teresa Zeberio, Izaskun Campo, Raquel del González, Leslie González, Pedro Blázquez, Cristina Rovira, Jordina Sitges, Marta Franch Sarto, Mireia Cabero, Almudena Mussetti, Alberto Montoro, Juan Sampol, Antonia Sureda, Anna Caballero, Dolores Martín García-Sancho, Alejandro |
Keywords: | Immunosupressió Limfomes Immunosuppression Lymphomas |
Issue Date: | 31-Mar-2025 |
Publisher: | American Society of Hematology |
Abstract: | We performed a retrospective multicenter study including 791 patients with relapsed/ refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as >= 3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as >= 3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024015415 |
It is part of: | Blood Advances, 2025, vol. 9, num. 13, p. 3281-3292 |
URI: | https://hdl.handle.net/2445/222831 |
Related resource: | https://doi.org/10.1182/bloodadvances.2024015415 |
ISSN: | 2473-9537 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
main (9).pdf | 1.49 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License